Your browser doesn't support javascript.
loading
Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer.
Karacin, Cengiz; Sunar, Veli; Urakci, Zuhat; Yilmaz, Ali; Ayhan, Murat; Ersoy, Mustafa; Guven, Deniz Can; Erturk, Ismail; Durmus, Yasin; Karacin, Pinar; Boran, Nurettin; Ustun, Yaprak Engin; Meydan, Mutlu; Dogan, Mutlu; Oksuzoglu, Berna; Ates, Ozturk; Karaca, Mustafa; Uncu, Dogan; Ergun, Yakup; Arik, Zafer.
Affiliation
  • Karacin C; Department of Medical Oncology, University of Health Sciences, Dr Abdurrahman Yurtaslan Ankara Oncology Training & Research Hospital, Ankara, Turkey.
  • Sunar V; Depatment of Medical Oncology, Losante Children & Adult Hospital, Ankara, Turkey.
  • Urakci Z; Departmen of Medical Oncology, Dicle University, Diyarbakir, Turkey.
  • Yilmaz A; Department of Medical Oncology, Atatürk University Training Hospital, Erzurum, Turkey.
  • Ayhan M; Department of Medical Oncology, Kartal Training & Research Hospital, Istanbul, Turkey.
  • Ersoy M; Department of Medical Oncology, Osmangazi University, Eskisehir, Turkey.
  • Guven DC; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
  • Erturk I; Department of Medical Oncology, University of Health Sciences, Gulhane Training & Research Hospital, Ankara, Turkey.
  • Durmus Y; Department of Gynecology, Etlik Zubeyde Hanim Training & Research Hospital, Ankara, Turkey.
  • Karacin P; Department of Gynecology, Etlik Zubeyde Hanim Training & Research Hospital, Ankara, Turkey.
  • Boran N; Department of Gynecology, Etlik Zubeyde Hanim Training & Research Hospital, Ankara, Turkey.
  • Ustun YE; Department of Gynecology, Etlik Zubeyde Hanim Training & Research Hospital, Ankara, Turkey.
  • Meydan M; Department of Gynecology, Zekai Tahir Burak Training & Research Hospital, Ankara, Turkey.
  • Dogan M; Department of Medical Oncology, University of Health Sciences, Dr Abdurrahman Yurtaslan Ankara Oncology Training & Research Hospital, Ankara, Turkey.
  • Oksuzoglu B; Department of Medical Oncology, University of Health Sciences, Dr Abdurrahman Yurtaslan Ankara Oncology Training & Research Hospital, Ankara, Turkey.
  • Ates O; Department of Medical Oncology, University of Health Sciences, Dr Abdurrahman Yurtaslan Ankara Oncology Training & Research Hospital, Ankara, Turkey.
  • Karaca M; Department of Medical Oncology, Antalya Training & Research Hospital, Antalya, Turkey.
  • Uncu D; Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara, Turkey.
  • Ergun Y; Department of Medical Oncology, Antalya City Hospital, Antalya, Turkey.
  • Arik Z; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Future Oncol ; 20(4): 207-214, 2024 Feb.
Article in En | MEDLINE | ID: mdl-38328890
ABSTRACT

Aim:

To investigate the efficacy and safety of bevacizumab in patients with recurrent low-grade serous ovarian carcinoma. Materials &

methods:

The data of patients who received at least two cycles of bevacizumab in combination with chemotherapy were retrospectively recorded.

Results:

The median age of 51 patients was 56 (range 33-75) years. The complete response rate was 10.4% and the partial response rate was 43.7%. The objective response rate was 54.1%. Median progression-free survival was 15.9 months (95% CI 9.1-22.6) and median overall survival was 42.5 months (95% CI 37.2-47.8).

Conclusion:

Bevacizumab with chemotherapy is an effective option for treating recurrent ovarian low-grade serous carcinoma.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Peritoneal Neoplasms / Cystadenocarcinoma, Serous Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Future Oncol Year: 2024 Document type: Article Affiliation country: Turkey Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Peritoneal Neoplasms / Cystadenocarcinoma, Serous Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Future Oncol Year: 2024 Document type: Article Affiliation country: Turkey Country of publication: United kingdom